• Gossamer Bio plans a virtual special shareholder meeting in 2026 to seek approval tied to its Aug. 20 private placement.
• Vote on authorizing common stock issuance from exercises of Pre-Funded Warrants, FDA Approval Warrants, and conversions of Series A-1, A-2, A-3 preferred.
• Private placement includes an initial $25 million issuance of pre-funded warrants at USD 0.14 per underlying common share.
• Second closing targets about USD 125 million upon FDA NDA filing acceptance for seralutinib in PAH, with additional FDA Approval Warrants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001728117-26-000086), on September 03, 2026, and is solely responsible for the information contained therein.